ArticleseJobs survey: 7 out of 10 employers will offer employees benefits during the Easter holidays. Cash bonuses, gift vouchers and baskets with seasonal products…
ArticleseJobs x Up Romania survey: 41% of employees are dissatisfied and very dissatisfied with their current job
ArticlesBCR Leasing offers microenterprises and PFA clients 100% digital access to active financing contracts, directly in the George ecosystem
ArticlesExtended update for Mercedes-Benz EQS
ArticlesThe art of communication for leaders: the essence of effective leadership
InterviewsHow do we evaluate shares in 2024? Opportunities vs. risks
InterviewsEmpowering your digital journey with SoftwareOne, globally and locally. Turn vision into reality with a valuable recipe
InterviewsNoventiq: Unlocking Romania's Digital Potential
InterviewsStrauss Romania: Evolving the consumers coffee experience is crucial
InterviewsA long term partnership is better than the commercial value of a deal
NewsOrange announces a new portfolio with fiber and TV subscriptions with 4 simplified packages, at affordable prices and Netflix included
News25 years of DENT ESTET in Romania - Investments of tens of millions of euros in the medical infrastructure and hundreds of thousands of…
NewsIrina Peptine is the new Marketing Director of Schneider Electric Romania, Moldova and Armenia
NewsBusiness Evolution, the road show on "Financing. Digitization. Efficient management", arrives for the first time in Suceava on 24 April 2024
NewsFAST FORWARD. THE ORGANIZATION OF THE FUTURE - 20th EDITION

Despite the boom on the capital markets, the global biotechnology industry needs a new paradigm of research and development

ERNST & YOUNG SRL

7 Jul 2014

The global biotechnical industry had a powerful comeback in 2013, with the companies listed on the stock market registering a two-figure rise in incomes and a radical increase in attracted funds.

A big part of this evolution was generated by a relatively small number of companies in the commercial phase. This puts extra pressure on the rest of the industry to obtain a bigger efficiency in the development of new drugs – shows the 28th annual EY report regarding the biotechnological industry – ‘Beyond borders: unlocking value’.

For more information, please see the Romanian version of the article, here.

Authors

foto

ERNST & YOUNG SRL

ASSURANCE SERVICES Statutory audits; Audits of IFRS or US GAAP…

See all published materials

View company profile

Tags : biotehnologie

© 2024, DoingBusiness.ro